Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(19 sites)
United States
Mount Sinai Cancer Center ( Site 0029), Miami Beach, Florida Australia
Gallipoli Medical Research Ltd ( Site 0204), Brisbane, Queensland Epworth Freemasons ( Site 0207), East Melbourne, Victoria Israel
Rambam Health Care Campus ( Site 1422), Haifa Edith Wolfson Medical Center ( Site 1423), Holon Japan
Hokkaido University Hospital ( Site 1609), Sapporo, Hokkaido Iwate Medical University Hospital ( Site 1610), Shiwa-gun, Iwate Saitama Medical University International Medical Center ( Site 1607), Hidaka, Saitama Cancer Institute Hospital of JFCR ( Site 1614), Koto, Tokyo Niigata Cancer Center Hospital ( Site 1608), Niigata South Korea
Severance Hospital ( Site 2302), Seodaemun-Gu, Seoul Keimyung University Dongsan Hospital ( Site 2304), Daegu, Taegu-Kwangyokshi Seoul National University Hospital ( Site 2301), Seoul Asan Medical Center ( Site 2305), Seoul Samsung Medical Center ( Site 2303), Seoul Switzerland
Inselspital Bern ( Site 3504), Bern, Canton of Bern Ospedale Regionale Bellinzona e Valli ( Site 3501), Bellinzona, Canton Ticino Kantonsspital Graubünden ( Site 3503), Chur, Kanton Graubünden Taiwan
Linkou Chang Gung Memorial Hospital ( Site 2605), Taoyuan District